AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for 5'-AMP-activated protein kinase catalytic subunit alpha-2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P54646

UPID:

AAPK2_HUMAN

Alternative names:

Acetyl-CoA carboxylase kinase; Hydroxymethylglutaryl-CoA reductase kinase

Alternative UPACC:

P54646; Q9H1E8; Q9UD43

Background:

The 5'-AMP-activated protein kinase catalytic subunit alpha-2, also known as Acetyl-CoA carboxylase kinase and Hydroxymethylglutaryl-CoA reductase kinase, is a pivotal enzyme in cellular energy homeostasis. It activates energy-producing pathways while inhibiting energy-consuming processes in response to low ATP levels. This protein kinase phosphorylates various metabolic enzymes and transcription regulators, influencing lipid synthesis, glucose uptake, and cell growth.

Therapeutic significance:

Understanding the role of 5'-AMP-activated protein kinase catalytic subunit alpha-2 could open doors to potential therapeutic strategies. Its regulatory function in energy metabolism and cell proliferation makes it a promising target for addressing metabolic disorders and cancer.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.